[{"id":"b753de45-c308-492f-a27a-55ed591ad6dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01625260","created_at":"2022-05-30T00:54:59.134Z","updated_at":"2024-07-02T16:37:26.263Z","phase":"Phase 1/2","brief_title":"A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer","source_id_and_acronym":"NCT01625260","lead_sponsor":"Altor BioScience","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • ALT-801"],"overall_status":"Unknown status","enrollment":" Enrollment 52","initiation":"Initiation: 04/01/2012","start_date":" 04/01/2012","primary_txt":" Primary completion: 04/01/2015","primary_completion_date":" 04/01/2015","study_txt":" Completion: 03/01/2018","study_completion_date":" 03/01/2018","last_update_posted":"2017-01-24"}]